• Plus Therapeutics Inc PSTV.OQ reported a quarterly adjusted loss of 37 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.00. The mean expectation of four analysts for the quarter was for a loss of 56 cents per share. Wall Street expected results to range from -78 cents to -35 cents per share.

• Revenue rose 17.4% to $1.46 million from a year ago; analysts expected $1.52 million.

• Plus Therapeutics Inc's reported EPS for the quarter was a loss of 37 cents​.

• The company reported a quarterly loss of $2.87 million.

• Plus Therapeutics Inc shares had fallen by 13.7% this quarter and lost 28.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Plus Therapeutics Inc is $26.00

This summary was machine generated from LSEG data November 15 at 02:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)